The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This pathway appears to be partly responsible for the beneficial clinical effects of iron chelators observed in several experimental infection systems (Mencacci et al., 1997; Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al., 2013; Nairz et al., 2013).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Ibrahim et al., 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Schaible, U. E., & Kaufmann, S. H. E. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1046 · Cited by 945
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717 · cited 2×
“Furthermore, it is known that deferasirox chelation is specific for iron and that other trace metals and cations are not affected by the drug (27, 28).”
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369 · cited 2×
“Alternatively, the enhanced efficacy of deferasirox in the diabetic ketoacidotic mouse model might reflect the ability of this iron chelator to efficiently chelate serum iron previously freed by proton-mediated dissociation from iron-sequestering proteins (2, 16, 17).”
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340 · cited 2×
“The potential therapeutic role of iron chelation therapy for mucormycosis was initially obscured by the paradoxically increased risk of developing mucormycosis during treatment with deferox-amine (18).”
Research works printed but not linked: 4
- Ganz, 2006, Curr. Top. Microbiol. Immunol., 306, 183
- Artis, 1982, Diabetes., 31, 1109, 10.2337/diacare.31.12.1109 · doi:10.2337/diacare.31.12.1109 · Paper page
- Fu, 2004, FEMS Microbiol. Lett., 235, 169
- Ibrahim, A.S., et al. 2000. Comparison of amphotericin B and amphotericin B lipid complex in the treatment of murine-induced zygomycosis. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17–20. Toronto, Ontario, Canada. American Society of Microbiology. Abstract 1681.
Cited by
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Ibrahim, A. S., Spellberg, B., Walsh, T. J., & Kontoyiannis, D. P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir865 · Cited by 824
“chelators, such as deferiprone and deferasirox [24, 25], which are not used by Mucorales as xenosiderophores.”
BackgroundSelf-citationGuidelines for the Management of Transfusion Dependent Thalassaemia (TDT)
Cappellini, M. D., Cohen, A. R., Porter, J. B., Taher, A. T., & Viprakasit, V. (2014) · Cited by 726
Challenges in the diagnosis and treatment of mucormycosis
Skiada, A., Lass-Floerl, C., Klimko, N., Ibrahim, A., Roilides, E., & Petrikkos, G. (2018) · Medical Mycology · doi:10.1093/mmy/myx101 · Cited by 568
Self-citationRecent Advances in the Management of Mucormycosis: From Bench to Bedside
Spellberg, B., Walsh, T. J., Kontoyiannis, D. P., Edwards, Jr., & Ibrahim, A. S. (2009) · Clinical Infectious Diseases · doi:10.1086/599105 · Cited by 548
“0% for placebo) [21].”
Self-citationSiderophores in Fungal Physiology and Virulence
Haas, H., Eisendle, M., & Turgeon, B. G. (2008) · Annual Review of Phytopathology · doi:10.1146/annurev.phyto.45.062806.094338 · Cited by 449
The struggle for iron - a metal at the host-pathogen interface: Iron at the host-pathogen interface
Nairz, M., Schroll, A., Sonnweber, T., & Weiss, G. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2010.01529.x · Cited by 398
“Studies in mice extend these findings to mucormycosis, in which the application of an iron chelator results in an improved survival paralleled by Th1/Th2 shift towards the Th1 phenotype and increased expression of protective, pro-inflammatory cytokines (Ibrahim et al., 2007).”
BackgroundGenomic Analysis of the Basal Lineage Fungus Rhizopus oryzae Reveals a Whole-Genome Duplication
Ma, L.-J., Ibrahim, A. S., Skory, C., Grabherr, M. G., Burger, G., Butler, M., Elias, M., Idnurm, A., Lang, B. F., Sone, T., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000549 · Cited by 379
“oryzae as a source of iron [36].”
Self-citationSkiada, A., Lanternier, F., Groll, A. H., Pagano, L., Zimmerli, S., Herbrecht, R., Lortholary, O., Petrikkos, G. L., & Leukemia*, O. B. O. T. T. E. C. O. I. I. (2013) · Haematologica · doi:10.3324/haematol.2012.065110 · Cited by 372
Iron at the interface of immunity and infection
Nairz, M., Haschka, D., Demetz, E., & Weiss, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00152 · Cited by 325
“This pathway appears to be partly responsible for the beneficial clinical effects of iron chelators observed in several experimental infection systems (Mencacci et al., 1997; Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al., 2013; Nairz et al., 2013).”
BackgroundThe endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice
Liu, M., Spellberg, B., Phan, Q. T., Fu, Y., Fu, Y., Lee, A. S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42164 · Cited by 324
“Furthermore, the iron chelator deferasirox, which reduces available serum iron, is effective in treating experimental hematogenously disseminated mucormycosis (13).”
BackgroundSelf-citationSpellberg, B., Ibrahim, A. S., Chin-Hong, P. V., Kontoyiannis, D. P., Morris, M. I., Perfect, J. R., Fredricks, D., & Brass, E. P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr375 · Cited by 308
Self-citationIron acquisition: a novel perspective on mucormycosis pathogenesis and treatment
Ibrahim, A. S., Spellberg, B., & Edwards, J. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283165fd1 · Cited by 264
Self-citationCotH3 mediates fungal invasion of host cells during mucormycosis
Gebremariam, T., Liu, M., Luo, G., Bruno, V., Phan, Q. T., Waring, A. J., Edwards, J. E., Filler, S. G., Yeaman, M. R., & Ibrahim, A. S. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71349 · Cited by 254
Self-citationAn update on iron chelation therapy.
(2012) · Europe PMC (PubMed Central) · doi:10.2450/2012.0008-12 · Cited by 233
The Iron age of host–microbe interactions
Soares, M. P., & Weiss, G. (2015) · The EMBO Reports · doi:10.15252/embr.201540558 · Cited by 227
“However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238].”
Muthu, V., Rudramurthy, S. M., Chakrabarti, A., & Agarwal, R. (2021) · Mycopathologia · doi:10.1007/s11046-021-00584-8 · Cited by 225
Mucormycosis in Organ and Stem Cell Transplant Recipients
Lanternier, F., Sun, H.-Y., Ribaud, P., Singh, N., Kontoyiannis, D. P., & Lortholary, O. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis195 · Cited by 212
“Indeed, the iron chelator deferasirox protects mice from mucormycosis [58].”
BackgroundMolecular mechanisms of mucormycosis—The bitter and the sweet
Baldin, C., & Ibrahim, A. S. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006408 · Cited by 212
Self-citationNairz, M., Schleicher, U., Schroll, A., Sonnweber, T., Theurl, I., Ludwiczek, S., Talasz, H., Brandacher, G., Moser, P. L., Muckenthaler, M. U., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121946 · Cited by 204
“DFX has been demonstrated to be effective in mucormycosis in animal models (Ibrahim et al., 2007).”
BackgroundFarmakiotis, D., & Kontoyiannis, D. P. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.011 · Cited by 200
Mucormycosis – from the pathogens to the disease
Binder, U., Maurer, E., & Lass-Flörl, C. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12566 · Cited by 194
“Sequence analysis of the Rhizopus-genome revealed two putative genes encoding heme oxygenases in Rhizopus [39,66].”
InfluentialKontoghiorghes, G., & Kontoghiorghe, C. (2020) · Cells · doi:10.3390/cells9061456 · Cited by 194
“In contrast to DFO related toxicity effects, both L1 and DFRA have been tested for the treatment of mucormycosis with encouraging results [255,256].”
ResultRhino-Orbital-Cerebral Mucormycosis
Gamaletsou, M. N., Sipsas, N. V., Roilides, E., & Walsh, T. J. (2012) · Current Infectious Disease Reports · doi:10.1007/s11908-012-0272-6 · Cited by 193
“Instead, deferasirox protects mice from mucormycosis through deprivation of iron from Rhizopus oryzae [127].”
BackgroundSipsas, N. V., Gamaletsou, M. N., Anastasopoulou, A., & Kontoyiannis, D. P. (2018) · Journal of Fungi · doi:10.3390/jof4030090 · Cited by 183
“Preclinical data in a mice model showed increased survival when receiving deferasirox, a new iron chelator that lacks siderophore capability [98].”
BackgroundMucormycosis in 2023: an update on pathogenesis and management
Alqarihi, A., Kontoyiannis, D. P., & Ibrahim, A. S. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1254919 · Cited by 181
“Increased availability of serum free iron levels in the host can enhance the ability of Mucorales to produce a rapidly invasive infection (Boelaert, 1994; Boelaert et al., 1994; Ibrahim et al., 2007).”
BackgroundSelf-citationCombination Echinocandin-Polyene Treatment of Murine Mucormycosis
Ibrahim, A. S., Gebremariam, T., Fu, Y., Edwards, J. E., & Spellberg, B. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01458-07 · Cited by 180
“DKA mice were infected via the tail vein with Rhizopus oryzae 99-892, a clinical isolate known to be virulent in our model (6, 9).”
BackgroundMethodSelf-citationMucormycosis: its contemporary face and management strategies
Sun, H.-Y., & Singh, N. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70316-9 · Cited by 175
Diabetes and mucormycosis: A complex interplay
Rammaert, B., Lanternier, F., Poirée, S., Kania, R. E., & Lortholary, O. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.01.002 · Cited by 175
“[98] Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al.”
BackgroundInfluentialCombination Therapy for Mucormycosis: Why, What, and How?
Spellberg, B., Ibrahim, A., Roilides, E., Lewis, R. E., Lortholary, O., Petrikkos, G., Kontoyiannis, D. P., & Walsh, T. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir885 · Cited by 171
Self-citationHassan, M. I. A., & Voigt, K. (2019) · Medical Mycology · doi:10.1093/mmy/myz011 · Cited by 171
Steinbrink, J. M., & Miceli, M. H. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.009 · Cited by 166
Recent Advances in the Treatment of Mucormycosis
Spellberg, B., & Ibrahim, A. S. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0129-9 · Cited by 165
Self-citationThe high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis
Ibrahim, A. S., Gebremariam, T., Lin, L., Luo, G., Husseiny, M. I., Skory, C. D., Fu, Y., French, S. W., Edwards, Jr., & Spellberg, B. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07234.x · Cited by 161
Self-citationDrosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis
Chamilos, G., Lewis, R. E., Hu, J., Xiao, L., Zal, T., Gilliet, M., Halder, G., & Kontoyiannis, D. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709578105 · Cited by 145
“Importantly, deferasirox is a iron chelator that, in contrast to deferoxamine, induces iron starvation to Zygomycetes and improves survival in a murine model of zygomycosis (21).”
BackgroundHsu, P.-C., Yang, C.-Y., & Lan, C.-Y. (2011) · Eukaryotic Cell · doi:10.1128/ec.00158-10 · Cited by 157
Mucormycosis of the Central Nervous System
Chikley, A., Ben‐Ami, R., & Kontoyiannis, D. P. (2019) · Journal of Fungi · doi:10.3390/jof5030059 · Cited by 155
“in vitro, and synergized with l-AmB to improve the survival of mice with experimental mucormycosis [129,130].”
BackgroundEpidemiology and Treatment of Mucormycosis
Lewis, R. E., & Kontoyiannis, D. P. (2013) · Future Microbiology · doi:10.2217/fmb.13.78 · Cited by 128
“Specifically, administration of newer iron chelators without xenosiderophore properties (deferiprone and deferasirox) have actually shown protective effects in animal models of invasive mucormycosis [41,49,50].”
Mucormycosis treatment: Recommendations, latest advances, and perspectives
Brunet, K., & Rammaert, B. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.101007 · Cited by 151
Lui, G. Y. L., Obeidy, P., Ford, S., Tselepis, C., Sharp, D. M., Jansson, P. J., Kalinowski, D. S., Kovačević, Ž., Lovejoy, D. B., & Richardson, D. R. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.081893 · Cited by 150
“….aspetjournals.org D ow nloaded from doses [i.e., 30 mg/kg per day for 8 weeks (Nick et al., 2009) or 10 mg/kg twice every day or every other day for 7 days (Ibrahim et al., 2007)] also did not significantly alter tissue iron levels, hematologic indices, or serum biochemical indices in mice.”
BackgroundFungal Infections in Leukemia Patients: How Do We Prevent and Treat Them?
Leventakos, K., Lewis, R. E., & Kontoyiannis, D. P. (2010) · Clinical Infectious Diseases · doi:10.1086/649879 · Cited by 147
Nairz, M., Theurl, I., Schroll, A., Theurl, M., Fritsche, G., Lindner, E., Seifert, M., Crouch, M.-L. V., Hantke, K., Akira, S., et al. (2009) · Blood · doi:10.1182/blood-2009-05-223354 · Cited by 146
Update on mucormycosis pathogenesis
Ibrahim, A. S., & Kontoyiannis, D. P. (2013) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000008 · Cited by 146
Self-citationIron restriction inside macrophages regulates pulmonary host defense against Rhizopus species
Andrianaki, A. M., Kyrmizi, I., Thanopoulou, K., Baldin, C., Drakos, E., Soliman, S. S. M., Shetty, A. C., McCracken, C., Akoumianaki, T., Stylianou, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05820-2 · Cited by 132
Self-citationEmerging therapies for multidrug resistant Acinetobacter baumannii
García‐Quintanilla, M., Pulido, M. R., López-Rojas, R., Pachón, J., & McConnell, M. J. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2012.12.002 · Cited by 141
Cerebro-rhino orbital mucormycosis: An update
Wali, U., Balkhair, A., & Al-Mujaini, A. S. (2012) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2012.01.003 · Cited by 138
Design of iron chelators with therapeutic application
Zhou, T., Ma, Y., Kong, X., & Hider, R. C. (2012) · Dalton Transactions · doi:10.1039/c2dt12159j · Cited by 136
Antifungal resistance in mucorales
Dannaoui, É. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.08.010 · Cited by 132
The role of chelators in preventing biofilm formation and catheter-related bloodstream infections
Raad, I. I., Fang, X., Keutgen, X. M., Jiang, Y., Sherertz, R., & Hachem, R. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32830634d8 · Cited by 119
Risk factors for mortality in patients with mucormycosis
Spellberg, B. J., Kontoyiannis, D. P., Fredricks, D. N., Morris, M. I., Perfect, J. R., Chin-Hong, P. V., Ibrahim, A. S., & Brass, E. P. (2012) · Medical Mycology · doi:10.3109/13693786.2012.669502 · Cited by 127
Self-citationBicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis
Gebremariam, T., Lin, L., Liu, M., Kontoyiannis, D. P., French, S., Edwards, J. E., Filler, S. G., & Ibrahim, A. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82744 · Cited by 120
Self-citationMucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic
Sharma, A., & Goel, A. (2022) · Folia Microbiologica · doi:10.1007/s12223-021-00934-5 · Cited by 126
“Deferasirox is a kind of iron-chelating agent that increases longevity in mice with diabetic ketoacidosis (Ibrahim et al. 2007).”
BackgroundIron and innate antimicrobial immunity-depriving the pathogen, defending the host
Nairz, M., Dichtl, S., Schroll, A., Haschka, D., Tymoszuk, P., Theurl, I., & Weiss, G. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.03.007 · Cited by 123
Microbial pathogens in the fungal kingdom
Heitman, J. (2011) · Fungal Biology Reviews · doi:10.1016/j.fbr.2011.01.003 · Cited by 123
“Studies capitalizing on insights from the genome sequences have begun to explore virulence mechanisms involving iron acquisition or its therapeutic deprivation (Ibrahim et al., 2007; Ibrahim et al., 2010), the roles of mating type in sex determination and possibly in virulence (Gryganskyi et al.”
BackgroundBlyth, C. C., Gilroy, N. M., Guy, S., Chambers, S. T., Cheong, E. Y. L., Gottlieb, T., McGuinness, S. L., & Thursky, K. (2014) · Internal Medicine Journal · doi:10.1111/imj.12598 · Cited by 118
Leal, S. M., Roy, S., Vareechon, C., Carrion, S. D., Clark, H., Lopez-Berges, M. S., diPietro, A., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003436 · Cited by 111
Human Fungal Pathogens of Mucorales and Entomophthorales
Mendoza, L., Vilela, R., Voelz, K., Ibrahim, A. S., Voigt, K., & Lee, S. C. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019562 · Cited by 109
Self-citationAntifungal therapy in invasive fungal infections
Chen, S. C. ‐., Playford, E. G., & Sorrell, T. C. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.06.002 · Cited by 110
“Oral deferasirox (US FDA-approved) is fungicidal against Zygomycetes at concentrations well below serum levels, protects mice with mucormycosis against death and is undergoing systematic clinical study; used alone or in combination with L-AMB, it is also effective in treatment of experimental IA [80 ,81].”
BackgroundPosaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis
Ibrahim, A. S., Gebremariam, T., Schwartz, J. A., Edwards, J. E., & Spellberg, B. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01124-08 · Cited by 108
“For the neutropenic model, mice were made neutropenic by a single intraperitoneal dose of 200 mg of cyclophosphamide/kg of body weight on day 2 relative to infection, resulting in approximately 7 days of neutropenia (6, 7, 12, 13).”
MethodSelf-citationTherapeutic Challenges of Non- Aspergillus Invasive Mold Infections in Immunosuppressed Patients
Lamoth, F., & Kontoyiannis, D. P. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01244-19 · Cited by 107
Schwartze, V. U., Winter, S., Shelest, E., Marcet‐Houben, M., Horn, F., Wehner, S., Linde, J., Valiante, V., Sammeth, M., Riege, K., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004496 · Cited by 104
“In addition, mucoralean fungi are also able to utilize deferoxamine, a bacterial siderophore which is used as an iron-chelator in human therapy [66,67].”
BackgroundNairz, M., Fritsche, G., Crouch, M.-L. V., Barton, H. C., Fang, F. C., & Weiss, G. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01337.x · Cited by 100
“The limitation of iron availability for pathogens is thus an effective strategy of innate host defence as shown in several in vitro and in vivo studies (Olakanmi et al., 2000; Ibrahim et al., 2007; Nairz et al., 2007; Paradkar et al., 2008; Kanti Das et al., 2008).”
BackgroundRecent Advances in the Pathogenesis of Mucormycoses
Petrikkos, G. L., & Tsioutis, C. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.03.009 · Cited by 97
Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis
Spellberg, B., Andes, D., Perez, M., Anglim, A., Bonilla, H., Mathisen, G. E., Walsh, T. J., & Ibrahim, A. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00361-09 · Cited by 93
“Mucormycosis is a life-threatening infection caused by fungi of the subphylum Mucormycotina, order Mucorales (5, 10, 12).”
BackgroundSelf-citationJose, A., Singh, S., Roychoudhury, A., Kholakiya, Y., Arya, S., & Roychoudhury, S. (2021) · Journal of Maxillofacial and Oral Surgery · doi:10.1007/s12663-021-01604-2 · Cited by 92
“Iron chelators like deferasirox and deferiprone may prove to be beneficial in many clinical studies [21, 46, 47].”
Backgroundde Léséleuc, L., Harris, G., KuoLee, R., & Chen, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00778-12 · Cited by 82
Gebremariam, T., Alkhazraji, S., Soliman, S. S. M., Gu, Y., Jeon, H. H., Zhang, L., French, S. W., Stevens, D. A., Edwards, J. E., Filler, S. G., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw1327 · Cited by 92
“The fixed organs were embedded in paraffin, and 5-mm sections were stained with hematoxylin and eosin (40).”
MethodSelf-citation‘Ride on the ferrous wheel’ – The cycle of iron in macrophages in health and disease
Nairz, M., Schroll, A., Demetz, E., Tancevski, I., Theurl, I., & Weiss, G. (2015) · Immunobiology · doi:10.1016/j.imbio.2014.09.010 · Cited by 89
Kontoghiorghes, G. J., Kolnagou, A., Skiada, A., & Petrikkos, G. (2010) · Hemoglobin · doi:10.3109/03630269.2010.483662 · Cited by 86
Targeting iron assimilation to develop new antibacterials
Foley, T. L., & Simeonov, A. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.708335 · Cited by 82
“oryzae challenges of diabeticketoacidotic mice demonstrated that administration of 10 at 10 mg/kg twice daily displayed effectiveness in resolving the disease state similar to a treatment with liposomal amphotericin B [53].”
BackgroundMolds: Hyalohyphomycosis, Phaeohyphomycosis, and Zygomycosis
Naggie, S., & Perfect, J. R. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.02.009 · Cited by 84
Genes, Pathways, and Mechanisms Involved in the Virulence of Mucorales
Lax, C., Arques, C. P., Navarro-Mendoza, M. I., Cánovas-Márquez, J. T., Tahiri, G., Pérez-Ruiz, J. A., Osorio-Concepción, M., Murcia, L., Navarro, E., Garre, V., et al. (2020) · Genes · doi:10.3390/genes11030317 · Cited by 81
“In vitro and in vivo studies demonstrated that deferasirox provoke iron starvation in Mucorales, suggesting that the administration of this chelator as an adjuvant could reduce the fungal dissemination [24].”
BackgroundAn encapsulation of iron homeostasis and virulence in Cryptococcus neoformans
Kronstad, J. W., Hu, G., & Jung, W. H. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.05.007 · Cited by 78
Zarember, K. A., Cruz, A. R., Huang, C.-Y., & Gallin, J. I. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01547-08 · Cited by 78
“deferiprone (12) and deferasirox (13) protected mice from”
BackgroundSynergy and antagonism between iron chelators and antifungal drugs in Cryptococcus
Lai, Y.-W., Campbell, L. T., Wilkins, M. R., Pang, C. N. I., Chen, S., & Carter, D. A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.06.012 · Cited by 73
L.S. Santos, A., L. Sodre, C., S. Valle, R., A. Silva, B., A. Abi-chacra, E., V. Silva, L., L. Souza-Goncalves, A., S. Sangenito, L., S. Goncalves, D., O.P. Souza, L., et al. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800609788 · Cited by 68
“Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B [200].”
BackgroundWermke, M., Schmidt, A., Middeke, J. M., Sockel, K., von Bonin, M., Schönefeldt, C., Mair, S., Plodeck, V., Laniado, M., Weiss, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1683 · Cited by 72
“A similar association was also reported by other groups using surrogate markers (27) or bone marrow iron (28) to define SIO and may relate to iron-mediated suppressionof the innate immune system(29)or to the fact that fungal growth is an iron-dependent process (30).”
ResultHost cell invasion in mucormycosis: role of iron
Ibrahim, A. S. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.004 · Cited by 76
“oryzae from acquiring external iron) are protected from hematogenously disseminated mucormycosis [40 ,47].”
Self-citationHyperbaric oxygen therapy and other adjunctive treatments for zygomycosis
Tragiannidis, A., & Groll, A. H. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02986.x · Cited by 76
“Administration of free iron with deferiprone reversed protection, confirming that the mechanism of protection was iron chelation [50].”
BackgroundEfficacy of Liposomal Amphotericin B and Posaconazole in Intratracheal Models of Murine Mucormycosis
Luo, G., Gebremariam, T., Lee, H., French, S. W., Wiederhold, N. P., Patterson, T. F., Filler, S. G., & Ibrahim, A. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00313-13 · Cited by 73
“Additionally, neutropenic (26, 31, 32), corticosteroid-treated (33), and deferoxamine-treated mouse models (34), as well as a deferoxamine-treated guinea pig model (35, 36), have been described.”
BackgroundMethodResultSelf-citationJanjua, O. S., Shaikh, M. S., Fareed, M. A., Qureshi, S. M., Khan, M. I., Hashem, D., & Zafar, M. S. (2021) · Journal of Fungi · doi:10.3390/jof8010044 · Cited by 72
“, patients on renal replacement therapy and those receiving repeated transfusions), makes people more susceptible to mucormycosis [57].”
BackgroundThe role of iron and iron chelators in zygomycosis
Symeonidis, A. S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02976.x · Cited by 70
“Treatment with DFX resulted in significantly increased Th1 and Th2 splenocyte subpopulations, and in significantly higher splenic and kidney levels of the proinflammatory cytokines tumour necrosis factor-a and interferon-c, than those in mice treated with saturating iron or placebo [35].”
BackgroundFungicidal monoclonal antibody C7 interferes with iron acquisition in Candida albicans
Brena, S., Cabezas-Olcoz, J., Moragues, M. D., Fernández de Larrinoa, I., Domínguez, A., Quindós, G., & Pontón, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00892-10 · Cited by 69
“(13) evaluated the iron chelator deferasirox as a therapeutic adjuvant for mucormycosis, and they concluded that abrogation of iron acquisition by the agents of mucormycosis was a promising therapeutic strategy to improve clinical outcomes (13, 34).”
BackgroundTransferrin iron starvation therapy for lethal bacterial and fungal infections
Lin, L., Pantapalangkoor, P., Tan, B., Bruhn, K. W., Ho, T., Nielsen, T., Skaar, E. P., Zhang, Y., Bai, R., Wang, A., et al. (2014) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu049 · Cited by 68
Self-citationIbrahim, A. S., Gebremariam, T., French, S. W., Edwards, J. E., & Spellberg, B. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp426 · Cited by 68
Self-citationImmunomodulation as Therapy for Fungal Infection: Are We Closer?
Sam, Q. H., Yew, W. S., Seneviratne, C. J., Chang, M. W., & Chai, L. Y. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01612 · Cited by 68
Deferasirox (Exjade®) for the Treatment of Iron Overload
Cappellini, M. D., & Taher, A. T. (2009) · Acta Haematologica · doi:10.1159/000243801 · Cited by 69
“A pilot trial to investigate the efficacy and tolerability of deferasirox in the treatment of porphyria cutanea tarda is currently recruiting patients (ClinicalTrials.gov identifier: NCT00599326). Deferasirox has also been shown to significantly improve survival and decrease tissue fungal burden in mice infected with…”
BackgroundComparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis
Ibrahim, A. S., Gebremariam, T., Husseiny, M. I., Stevens, D. A., Fu, Y., Edwards, J. E., & Spellberg, B. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01488-07 · Cited by 67
“Other groups of mice were euthanized after 72 h of infection, prior to the initiation of death from infection in the placebo group, for the determination of tissue fungal burdens by quantitatively culturing gently homogenized organs (10) and for the determination of amphotericin B concentrations in harvested tissues b…”
MethodSelf-citationNew antifungal strategies: Drug combination and co-delivery
Zhu, P., Li, Y., Guo, T., Liu, S., Tancer, R. J., Hu, C., Zhao, C., Xue, C., & Liao, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114874 · Cited by 63
Ibrahim, A. S., Gebremariam, T., Luo, G., Fu, Y., French, S. W., Edwards, J. E., & Spellberg, B. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01577-10 · Cited by 63
“effect of dual therapy previously seen with LAmB plus Def (8)”
BackgroundInfluentialSelf-citationLiu, M., Lin, L., Gebremariam, T., Luo, G., Skory, C. D., French, S. W., Chou, T.-F., Edwards, J. E., & Ibrahim, A. S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004842 · Cited by 62
“The mean fluorescence intensities of 10(4) events were calculated using CELLQUEST software [20,63].”
BackgroundMethodSelf-citationAgents of Mucormycosis and Entomophthoramycosis
Kontoyiannis, D. P., & Lewis, R. E. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00259-9 · Cited by 62
Busca, A., Falda, M., Manzini, P., D'Antico, S., Valfrè, A., Locatelli, F., Calabrese, R., Chiappella, A., D'Ardia, S., Longo, F., et al. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.09.011 · Cited by 58
“Alternatively, the possibility that iron starvation might slow the growth of fungal hyphae is intriguing [29,30].”
BackgroundEpidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review
Liang, M., Xu, J., Luo, Y., & Qu, J. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2396570 · Cited by 59
“The sensitivity of Rhizopus arrhizus to isavuconazole was similar to that of Rhizopus spp. but significantly greater than that of Mucor spp. and Mucor circinelloides [133–135].”
ResultCombination antifungal therapy for invasive fungal infections in children and adults
Hatipoğlu, N., & Hatipoğlu, H. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.29 · Cited by 58
Iron Pathways and Iron Chelation Approaches in Viral, Microbial, and Fungal Infections
Chhabra, R., Saha, A., Chamani, A., Schneider, N., Shah, R., & Nanjundan, M. (2020) · Pharmaceuticals · doi:10.3390/ph13100275 · Cited by 58
“However, other iron chelators, such as DFP and DFRA, were successful in reducing virulence and improved survival in an in vivo diabetic ketoacidotic mouse model [182,183].”
BackgroundSuccessful treatment of periodontal mucormycosis: report of a case and literature review
McDermott, N. E., Barrett, J., Hipp, J., Merino, M. J., Lee, C. R., Waterman, P. E., Domingo, D. L., & Walsh, T. J. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.11.012 · Cited by 58
Connecting the Dots: Interplay of Pathogenic Mechanisms between COVID-19 Disease and Mucormycosis
Prakash, H., Skiada, A., Paul, R. A., Chakrabarti, A., & Rudramurthy, S. M. (2021) · Journal of Fungi · doi:10.3390/jof7080616 · Cited by 56
“Other iron chelators, such as deferasirox and deferiprone, showed reduced fungal burden in tissues and increased the survival rate in DKA and neutropenic mouse models of mucormycosis [77,80].”
BackgroundFuture Directions in Mucormycosis Research
Kontoyiannis, D. P., Lewis, R. E., Lotholary, O., Spellberg, B. J., Πετρίκκος, Γ., Roilides, E., Ibrahim, A. S., & Walsh, T. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir886 · Cited by 56
“Because deferasirox has activity against Zygomycetes [19, 20], its use to treat iron overload in patients with hematologic malignancies could theoretically decrease the occurrence of mucormycosis.”
Self-citationThe mucormycete–host interface
Ibrahim, A. S., & Voelz, K. (2017) · Current Opinion in Microbiology · doi:10.1016/j.mib.2017.10.010 · Cited by 55
Self-citation
Metadata
- Authors
- Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J.
- Affiliations
- University of California, Los Angeles (US)
- Charles River Laboratories (United States) (US)
- National Center for Agricultural Utilization Research (US)
- Corresponding author
- Ibrahim, Ashraf S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2649-2657
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1957543
- OpenAlex
- W2113977119
- Cited by
- 308
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 21 · 2020: 15 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 20 · 2013: 23 · 2012: 25
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- National Institute of Allergy and Infectious Diseases (R01 AI63503-01A2, R01AI019990, K08AI060641, AI-063382, R01-AI19990, R21AI064716, R01AI063382, R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- mucormycosis, deferasirox, iron chelation, iron starvation, Mucorales, Rhizopus oryzae, liposomal amphotericin B, antifungal therapy, diabetic ketoacidosis, neutropenia, host inflammatory response, serum iron, adjunctive therapy
- MeSH terms
- Deferasirox, Amphotericin B, Animals, Benzoates, Diabetes Mellitus, Drug Therapy, Combination, Iron, Iron Chelating Agents, Liposomes, Male, Mice, Inbred BALB C, Mucorales, Mucormycosis, Triazoles, Survival Rate, Th1 Cells, Th2 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.